SLC5A2 and heart failure: Heart failure-specific trials, such as DAPA-HF[53] and EMPEROR-Reduced,[54] have also demonstrated that SGLT-2 inhibitors significantly reduce the risks of cardiovascular death and hospitalization in HF patients.